CA3102212A1 - Immunomodulatory compounds - Google Patents

Immunomodulatory compounds Download PDF

Info

Publication number
CA3102212A1
CA3102212A1 CA3102212A CA3102212A CA3102212A1 CA 3102212 A1 CA3102212 A1 CA 3102212A1 CA 3102212 A CA3102212 A CA 3102212A CA 3102212 A CA3102212 A CA 3102212A CA 3102212 A1 CA3102212 A1 CA 3102212A1
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
group
membered
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3102212A
Other languages
English (en)
French (fr)
Inventor
Nathanael Gray
Tinghu Zhang
Eric Fischer
Alyssa VERANO
Zhixiang HE
Guangyan DU
Katherine DONOVAN
Radoslaw Nowak
Jing Ting Christine YUAN
Hu Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA3102212A1 publication Critical patent/CA3102212A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3102212A 2018-06-29 2019-06-27 Immunomodulatory compounds Pending CA3102212A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862692176P 2018-06-29 2018-06-29
US62/692,176 2018-06-29
PCT/US2019/039509 WO2020006233A1 (en) 2018-06-29 2019-06-27 Immunomodulatory compounds

Publications (1)

Publication Number Publication Date
CA3102212A1 true CA3102212A1 (en) 2020-01-02

Family

ID=68987232

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3102212A Pending CA3102212A1 (en) 2018-06-29 2019-06-27 Immunomodulatory compounds

Country Status (8)

Country Link
US (1) US12234220B2 (enExample)
EP (1) EP3814330A4 (enExample)
JP (2) JP7328263B2 (enExample)
KR (1) KR102834593B1 (enExample)
CN (1) CN113166100A (enExample)
AU (1) AU2019293235B2 (enExample)
CA (1) CA3102212A1 (enExample)
WO (1) WO2020006233A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
CN113166100A (zh) * 2018-06-29 2021-07-23 达纳-法伯癌症研究所有限公司 免疫调节性化合物
KR20210152515A (ko) 2019-04-12 2021-12-15 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
AU2020392427B2 (en) * 2019-11-27 2024-03-07 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
IL293530A (en) 2019-12-18 2022-08-01 Novartis Ag Derivatives of 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione and their uses
WO2022255889A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
AR126052A1 (es) 2021-06-03 2023-09-06 Novartis Ag Derivados de 3-(5-oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos
IL319458A (en) 2022-09-09 2025-05-01 Innovo Therapeutics Inc Compounds that reduce ck1α and dual ck1α/gspt1
CN116655595A (zh) * 2023-06-05 2023-08-29 中国人民解放军军事科学院军事医学研究院 2,6-哌啶二酮衍生物及其制备和用途
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
WO2008007979A1 (en) * 2006-07-12 2008-01-17 Auckland Uniservices Limited (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives
CA3017740A1 (en) 2016-03-16 2017-09-21 Pearlie BURNETTE Small molecules against cereblon to enhance effector t cell function
EP3455219A4 (en) * 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP3577109A4 (en) 2017-01-31 2020-11-18 Arvinas Operations, Inc. CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
CN113166100A (zh) * 2018-06-29 2021-07-23 达纳-法伯癌症研究所有限公司 免疫调节性化合物

Also Published As

Publication number Publication date
US20210284624A1 (en) 2021-09-16
JP7328263B2 (ja) 2023-08-16
KR20210027395A (ko) 2021-03-10
JP2023145694A (ja) 2023-10-11
KR102834593B1 (ko) 2025-07-16
AU2019293235A1 (en) 2020-12-17
CN113166100A (zh) 2021-07-23
US12234220B2 (en) 2025-02-25
WO2020006233A1 (en) 2020-01-02
JP2021530453A (ja) 2021-11-11
EP3814330A4 (en) 2022-07-20
EP3814330A1 (en) 2021-05-05
AU2019293235B2 (en) 2025-07-03

Similar Documents

Publication Publication Date Title
US12110292B2 (en) Ligands to cereblon (CRBN)
KR102834593B1 (ko) 면역조절 화합물
AU2019220632B2 (en) IRAK degraders and uses thereof
EP4051386A1 (en) Small molecule degraders of helios and methods of use
CA3102217A1 (en) Bispecific degraders
US20230158157A1 (en) Potent and selective degraders of alk
WO2020069106A1 (en) Degraders that target alk and therapeutic uses thereof
US20240376096A1 (en) Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
CA3172589A1 (en) Piperidine-2,6-diones as small molecule degraders of helios and methods of use
EP3986470A2 (en) Small molecule target bromo/acetyl proteins and uses thereof
CA3132348A1 (en) Degraders of fibroblast growth factor receptor 2 (fgfr2)
AU2019346595B2 (en) Macrocyclic inhibitors of ALK, TRKA, TRKB, TRKC and ROS1
CA3218951A1 (en) Degraders of wild-type and mutant forms of lrrk2 and uses thereof